source
- Alzheon seeks up to $500M in new financing after Phase 3 setback for Alzheimer’s drugAlzheon, a biotech based in Framingham, Massachusetts, has been pursuing an Alzheimer’s therapy for more than a decade. Its lead candidate recently failed to achieve the primary goals in a Phase 3…
- Owkin and Servier partner to use AI platform K Pro for oncology discovery and trial designOwkin, an AI drug-discovery CRO, has entered a new agreement with French pharmaceutical company Servier to license its AI scientist, K Pro, for use in Servier’s oncology research and clinical trial…